Cargando…

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study

OBJECTIVE: Despite frequent use of fingolimod (FTY) and dimethyl fumarate (DMF), studies comparing clinical efficacy and withdrawal rates of DMF and FTY concerning different pretreatment situations are rare. The aim of our study was to compare relapse occurrence and withdrawal rates of DMF and FTY i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diem, Lara, Daponte, Ariadne, Findling, Oliver, Miclea, Andrei, Briner, Myriam, Salmen, Anke, Gold, Ralf, Kilidireas, Constantinos, Chan, Andrew, Evangelopoulos, Maria Elftheria, Hoepner, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984136/ https://www.ncbi.nlm.nih.gov/pubmed/31937596 http://dx.doi.org/10.1212/NXI.0000000000000660

Ejemplares similares

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
por: Gili-Kovács, Judit, et al.
Publicado: (2021)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
por: Veselaj, Krenar, et al.
Publicado: (2020)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
por: Delgado, Silvia, et al.
Publicado: (2021)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate
por: Farley, Stephen, et al.
Publicado: (2019)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
por: Bagnoud, Maud, et al.
Publicado: (2020)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

Erratum to “A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod”
Publicado: (2021)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection
por: Pitarokoili, Kalliopi, et al.
Publicado: (2015)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
por: Gold, Ralf, et al.
Publicado: (2018)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Intermittent Atrioventricular Block following Fingolimod Initiation
por: Gialafos, E., et al.
Publicado: (2014)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis
por: Hoepner, Robert, et al.
Publicado: (2015)

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity
por: Miclea, Andrei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l1g5tgpds9q9go31557me9ksq9